ANXA5 and neoplasm: Results of the in vivo study included suppression of EAC tumor burden, enhanced apoptosis (Annexin V/PI), reduced IL-6 and TNF-α cytokines, and preserved liver/kidney function, confirming synergistic antitumor and immunomodulatory effects with a favorable biosafety profile [21].